Odyssey Therapeutics, Inc.
- Market cap
- $845.83M
- 52w range
- $15.10 - $29.05
- Sector
- Healthcare
- Data quality
- 58/100
- Moat score
- 12/100
- Debt / equity
- 0.15
- Analyst target
- $32.00
- Target upside
- +56.7%
- Analysts
- 3
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Valuation
Derived from filed metrics · Moderate confidence (58% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).